Eli Lilly and Novo Nordisk Stocks Diverge on Contrasting Growth Outlooks

A significant performance divergence has emerged between pharmaceutical rivals Eli Lilly (LLY) and Novo Nordisk (NVO), as investors weigh sharply contrasting growth trajectories and operational headwinds. While Eli Lilly has seen its shares gain 46.7% over the past year, Novo Nordisk's stock has declined 3.1% over the same period, according to an analysis by Investing.com.

A Tale of Two Forecasts

The split in market sentiment is rooted in fundamental differences in the companies' financial outlooks. The market is pricing in expectations for continued high growth at Lilly, while anticipating a rare contraction at Novo Nordisk.

Key comparative metrics highlight the gap:

• Revenue Growth: Eli Lilly's revenue is projected to increase by 30.3% next year, whereas Novo Nordisk is forecast to see a 6.5% revenue decline.
• Profitability: Lilly's earnings per share (EPS) are expected to surge by 49.3% next year. In contrast, Novo's EPS is forecast to fall by 6.6%.
• Valuation: The growth expectations are reflected in valuations. Lilly trades at a forward price-to-earnings (P/E) ratio of 32.6x, while Novo Nordisk trades at a much lower multiple of 14.3x.

Catalysts and Headwinds

Ad

Recent developments and upcoming events are fueling the divergence. Eli Lilly has benefited from strong Phase 3 trial results for its obesity drug candidate, retatrutide, which showed superior weight loss compared to Novo's Wegovy. Analysts at Bernstein also anticipate Lilly will raise its full-year guidance when it reports earnings on August 5, the same day as Novo.

Novo Nordisk, meanwhile, has faced a series of challenges, including four guidance cuts over the past year, significant job reductions, and a securities fraud class action lawsuit related to disclosures for its drug CagriSema. For its upcoming earnings, analysts see the benchmark for success as simply avoiding further negative revisions.

Implications for the Pair Trade

The opposing momentum complicates the classic "pair trade" strategy for the two stocks. Eli Lilly is priced for near-perfection, with its current share price just 8.4% below its consensus fair value estimate, leaving little room for error. Conversely, Novo Nordisk's stock is trading at a deep discount, with a potential 56.0% upside to its fair value estimate, but this depends entirely on the company's ability to stabilize its operations and reverse its negative trajectory.